comparemela.com

Latest Breaking News On - Low risk patients - Page 1 : comparemela.com

Repeat transcatheter aortic valve replacement after initial attempt is generally safe in patients with balloon-expandable valves

1. Redo-TAVR had low procedural complication rates and was comparable to native-TAVR in terms of risk of death and stroke at 30 days and 1 year. 2. Rates of moderate-to-severe aortic regurgitation were comparable between groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Transcatheter aortic valve replacement (TAVR) has become a standard treatment for aortic

Joint Statement on Aortic Valve Replacement in Low-Risk Patients Issued by Society of Thoracic Surgeons and European Association for Cardiothoracic Surgeons

The Society of Thoracic Surgeons and the European Association for Cardiothoracic Surgeons have issued a joint statement in response to the new research on aortic valve replacement in low-risk patients announced during the Transcatheter Cardiovascular Therapeutics Conference, TCT 2023, and recently published in The Annals of Thoracic Surgery.

Study supports minimally invasive procedure as aortic stenosis treatment

Study supports minimally invasive procedure as aortic stenosis treatment
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Largest US cardiac database shows excellent long-term survival after surgical aortic valve replacement

Largest US cardiac database shows excellent long-term survival after surgical aortic valve replacement
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Ropeg superior to phlebotomy alone in maintaining hematocrit control in polycythemia vera

Italy: Exposure to low-dose ropeginterferon alfa-2b (ropeg) is more effective than the standard treatment of phlebotomy and aspirin in patients with low-risk polycythemia vera (PV), a 24-month trial.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.